129 related articles for article (PubMed ID: 29397631)
21. Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.
Strumberg D; Schultheis B; Scheulen ME; Hilger RA; Krauss J; Marschner N; Lordick F; Bach F; Reuter D; Edler L; Mross K
Int J Clin Pharmacol Ther; 2010 Jul; 48(7):473-5. PubMed ID: 20557849
[No Abstract] [Full Text] [Related]
22. Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers.
Cheng CC; Lin HC; Tsai KJ; Chiang YW; Lim KH; Chen CG; Su YW; Peng CL; Ho AS; Huang L; Chang YC; Lin HC; Chang J; Chang YF
Mol Carcinog; 2018 Nov; 57(11):1588-1598. PubMed ID: 30035369
[TBL] [Abstract][Full Text] [Related]
23. EGFR targeting of solid tumors.
Rocha-Lima CM; Soares HP; Raez LE; Singal R
Cancer Control; 2007 Jul; 14(3):295-304. PubMed ID: 17615536
[TBL] [Abstract][Full Text] [Related]
24. Advanced or metastatic pancreatic cancer: molecular targeted therapies.
Bayraktar S; Rocha-Lima CM
Mt Sinai J Med; 2010; 77(6):606-19. PubMed ID: 21105124
[TBL] [Abstract][Full Text] [Related]
25. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
[TBL] [Abstract][Full Text] [Related]
26. Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER.
Moradi-Kalbolandi S; Hosseinzade A; Salehi M; Merikhian P; Farahmand L
J Pharm Pharmacol; 2018 Jul; 70(7):841-854. PubMed ID: 29574771
[TBL] [Abstract][Full Text] [Related]
27. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
28. Epidermal Growth Factor Receptor and Its Role in Pancreatic Cancer Treatment Mediated by Nanoparticles.
Grapa CM; Mocan T; Gonciar D; Zdrehus C; Mosteanu O; Pop T; Mocan L
Int J Nanomedicine; 2019; 14():9693-9706. PubMed ID: 31849462
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor-targeted therapy for pancreatic cancer.
Xiong HQ; Abbruzzese JL
Semin Oncol; 2002 Oct; 29(5 Suppl 14):31-7. PubMed ID: 12422311
[TBL] [Abstract][Full Text] [Related]
30. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
Chen YM
J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor based active targeting: a paradigm shift towards advance tumor therapy.
Habban Akhter M; Sateesh Madhav N; Ahmad J
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1188-1198. PubMed ID: 29991287
[TBL] [Abstract][Full Text] [Related]
32. Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better….
Di Maio M; Morabito A; Piccirillo MC; Daniele G; Giordano P; Costanzo R; Sandomenico C; Montanino A; Rocco G; Perrone F
Curr Pharm Des; 2014; 20(24):3901-13. PubMed ID: 24191956
[TBL] [Abstract][Full Text] [Related]
33. HSP90 inhibitors induce desensitization of EGF receptor via p38 MAPK-mediated phosphorylation at Ser1046/1047 in human pancreatic cancer cells.
Adachi S; Yasuda I; Nakashima M; Yamauchi T; Yamauchi J; Natsume H; Moriwaki H; Kozawa O
Oncol Rep; 2010 Jun; 23(6):1709-14. PubMed ID: 20428829
[TBL] [Abstract][Full Text] [Related]
34. Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy.
Funatomi H; Itakura J; Ishiwata T; Pastan I; Thompson SA; Johnson GR; Korc M
Int J Cancer; 1997 Jul; 72(3):512-7. PubMed ID: 9247297
[TBL] [Abstract][Full Text] [Related]
35. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
Gui T; Shen K
Cancer Epidemiol; 2012 Oct; 36(5):490-6. PubMed ID: 22818908
[TBL] [Abstract][Full Text] [Related]
36. Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma.
Muslimov GF
Bull Exp Biol Med; 2008 Apr; 145(4):535-8. PubMed ID: 19110611
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future.
Cohenuram M; Saif MW
JOP; 2007 Jan; 8(1):4-15. PubMed ID: 17228128
[TBL] [Abstract][Full Text] [Related]
38. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
[TBL] [Abstract][Full Text] [Related]
39. Targeted Therapy of Head and Neck Cancer.
Rieke DT; Klinghammer K; Keilholz U
Oncol Res Treat; 2016; 39(12):780-786. PubMed ID: 27889751
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs.
Ciardiello F; Tortora G
Eur J Cancer; 2003 Jul; 39(10):1348-54. PubMed ID: 12826036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
